Enfortumab vedotin targets Nectin-4 on tumor cells; after internalization it releases MMAE, which binds tubulin to depolymerize microtubules and cause G2/M arrest and apoptosis. Tubulin is the intracellular effector, not the targeting antigen determining which cells are killed.